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The clinical applications of stem cells
At present, stem cell therapies in veterinary patients are 
not rigorously supervised by regulatory agencies in any 
country [1]. Unfortunately, this has led to the implemen-
tation of some therapies that have not demonstrated 
eﬃ   cacy  in vitro or in preclinical animal studies. In 
general, the thera  peutic role of stem cells in regenerative 
medicine is not fully understood. It is unclear whether 
stem cells ultimately function once diﬀ  erentiated into a 
tissue-speciﬁ  c cell such as a tenocyte or whether they 
primarily improve tissue repair through secretion of 
immuno  modulatory and bioactive trophic factors or 
whether a combination of the two mechanisms occurs 
[2]. Th  ese questions are not purely academic in nature, 
because if stem cells are truly immunomodulatory, then 
allogeneic transplantations should be possible. Safe and 
eﬃ     cacious applications of allogeneic stem cells would 
imply that oﬀ   -the-shelf stem cell products could be 
developed for increased availability and rapid 
implementation of stem cell therapies early in a disease 
course. Th   e potential for allogeneic stem cells to be more 
cost-eﬀ  ective than autogenous stem cells is questionable. 
For allogeneic cells, there would be no costs associated 
with a tissue harvest procedure, but there would be 
added expenses of ensuring that the stem cell product 
was free of disease and of storing the stem cells until sale.
Th  e therapeutic application of stem cell-based tech-
nolo  gies in veterinary medicine was ﬁ  rst used by Herthel 
[3] to treat equine suspensory ligament desmitis. Th  is 
application involved direct injection of large volumes (20 
to 60 mL) of naïve bone marrow aspirate obtained from 
the sternum into an injured ligament. In this report of an 
uncontrolled, nonrandomized case series, the technique 
appeared to improve return to athletic function rates 
over conventional therapies. However, it is unlikely that 
the observed results were due to stem cells, as it became 
known that there are very few stem cells in bone marrow 
aspirate. Mesenchymal stem cells (MSCs) represent a 
very small fraction of the total population of nucleated 
cells from bone marrow from humans [4] and cats [5] 
and are presumed to be similar in other species, including 
the horse. Th   ese studies indicate that 0.001% to 0.01% of 
mononuclear cells isolated from a Ficoll density gradient 
of bone marrow aspirate are MSCs. Th  e percentage of 
MSCs in raw bone marrow aspirate would be less than 
0.001% to 0.01% because the technique of Ficoll density 
gradient isolation omits several types of nucleated cells, 
including granulocytes and immature myeloid precur-
sors. Any clinical eﬀ  ect of bone marrow aspirate might be 
attributed to the numerous bioactive substances in the 
acellular fraction such as growth factors produced by 
cells or platelets. For example, bone marrow aspirate that 
is rendered acellular through freeze-thaw has some 
stimulatory eﬀ  ects on matrix synthesis when applied in 
vitro to tendons and ligaments [6,7].
Stem cell products in clinical use
In veterinary patients, three MSC-based approaches are 
currently used for the treatment of tendon, ligament, or 
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previously, there are research-based but no clinical 
reports that document the use of stem cells to enhance 
fracture repair, nor are there any reports in cardio  vas-
cular, gastrointestinal, or neuroendocrine body systems. 
Th  e ﬁ  rst MSC-based method relies on a culture-expan-
ded cell population derived from bone marrow aspirate, 
the second is another bone marrow aspirate-based 
approach using a concentrated mixed cell population 
derived from bone marrow aspiration, and the third 
method employs a mixed nucleated cell population 
derived from adipose tissue. Each technique has its 
strengths and weaknesses. Embryonic stem (ES) cells, 
induced pluripotent stem (iPS) cells, and cord blood-
derived cells are also beginning to be investigated in the 
laboratory but have not yet been applied to the clinical 
scenario.
Culture-expanded bone marrow-derived mesenchymal 
stem cells
Bone marrow-derived  mesenchymal stem cells (BM-
MSCs) have the advantages of being easily and relatively 
noninvasively obtained and have a greater capacity to 
diﬀ   erentiate into tissue types of the musculoskeletal 
system in comparison with other MSCs [8-10]. Further-
more, BM-MSCs have received the most scientiﬁ  c atten-
tion and hence are the best characterized. One dis-
advantage of culture-expanded BM-MSCs is the time lag 
of 3 to 6 weeks from bone marrow aspirate until treat-
ment. Th   is time lag is necessitated by the time required 
to grow the MSCs. Bone marrow is collected from the 
sternum or the tuber coxae of horses under sedation or 
can be collected intraoperatively if the horse is already 
anesthetized. Th   e horse has seven marrow spaces in the 
sternum, and marrow spaces 3 to 5 are the largest (up to 
5 cm in diameter). Ultrasonography can be used to isolate 
the marrow space but is not necessary if one is familiar 
with the regional anatomy. Bone marrow is typically 
aspirated from the proximal humerus, proximal femur, or 
tuber coxae in dogs.
Tendonitis
Th   e use of culture-expanded BM-MSCs for the treatment 
of tendon injuries is supported by experimental investi-
gations in horses and laboratory animals in which MSCs 
were implanted in surgically or collagenase-induced 
tendon lesions. Th  ese studies have shown favorable 
eﬀ  ects on tissue organization, composition, and mech-
anics of MSC-implanted tendons and ligaments [11-14]. 
Th   ese studies vary in experimental design with respect to 
the number of BM-MSCs implanted (0.5 to 10 × 106), 
vehicle for suspension (plasma, phosphate-buﬀ  ered 
saline, bone marrow supernatant), and time post-injury 
to injection (up to 2 weeks). Th  e clinical application of 
BM-MSCs was ﬁ  rst reported in 2003 [15]. More recently, 
a small case control study (n = 11) demonstrated that, as 
a result of BM-MSCs, 90% of treated horses successfully 
returned to pre-injury athletic function and race horses 
suﬀ   ered no re-injury of the superﬁ   cial digital ﬂ  exor 
tendon after 2 years whereas all of the horses of a control 
population suﬀ  ered from re-injury [16]. In an unblinded, 
uncon  trolled case series, Godwin and Smith [17] 
reported on 141 horses treated with cultured BM-MSCs 
with at least a 3-year follow-up. Th   e authors reported a 
signiﬁ  cant decrease in re-injury rate for National Hunt 
race horses but not ﬂ  at-track Th   oroughbred race horses 
treated with BM-MSCs when compared with conven-
tionally treated historical controls (23% to 66%). To date, 
preclinical and clinical studies have focused on the ability 
of stem cells to enhance tissue regeneration and have not 
investigated the potential immuno  modu  latory roles of 
stem cells for tendon repair. Th   is is most likely simply a 
matter of timing, with the concept of immunomodulation 
being more recent than the more traditional paradigm of 
stem cells diﬀ   erentiating and functioning as tissue-
speciﬁ   c cells. Although the above-mentioned studies 
have docu  mented stemness of the cells to varying degrees, 
tumor, ectopic bone, or cartilage formation has not been 
ob  served in either clinical or research investigations.
Cartilage injury/osteoarthritis
Culture-expanded BM-MSCs have been evaluated in an 
equine model of acute cartilage injury in which 15-mm-
diameter full-thickness articular cartilage defects were 
created on the lateral trochlear ridge of the femur [18]. 
Th   e BM-MSCs were implanted in autogenous ﬁ  brin as a 
scaﬀ  old in one limb, and the opposite limb was grafted 
with autogenous ﬁ   brin alone. At 30-day re-check 
arthros  copy, arthroscopy scores and biopsy assessments 
for the BM-MSCs lesions were signiﬁ  cantly better than 
ﬁ   brin-only control grafts. However, at 8 months, no 
signiﬁ  cant diﬀ  erences between the two groups in histo-
logic or biochemical composition were observed. In an 
equine model of early osteoarthritis (OA), a direct 
comparison between BM-MSCs and adipose-derived 
stromal vascular fraction (AD-SVF) cells was made [19]. 
Th  e two stem cell preparations were injected directly 
into aﬀ  ected joints 14 days after induction of OA. Joints 
treated with BM-MSCs showed signiﬁ  cantly less syno-
vial eﬀ  usion and signiﬁ    cantly lower prostaglandina E2 
(PGE2) concentra  tions in comparison with those 
treated with AD-SVF cells. No diﬀ  erences in cartilage 
biochemistry or histo  logy, synovial ﬂ   uid analysis, or 
other clinical parameters were observed. It is interesting 
to note that synovial ﬂ  uid PGE2 concentrations, though 
not directly investigated in the study, were decreased by 
BM-MSC treatment because PGE2 is one mechanism 
by which BM-MSCs modulate immune cells and exert 
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suppression of lymphocyte proliferation and T-cell 
activation [2,20]. Several other preclinical studies in OA 
models using goats, sheep, rabbits, and rats have demon-
strated the capacity for BM-MSCs to enhance regenera-
tion of cartilage and even meniscus [21,22]. Combined, 
these studies suggest that BM-MSCs have the dual 
function in an articular environ  ment to modulate the 
local T cell-mediated immuno  logical response and to 
enhance tissue regeneration. Long-term studies using BM-
MSCs in naturally occur  ring articular cartilage injuries in 
veterinary and human patients are required to demon-
strate restoration of joint function, decreased articular 
pain, and durability of BM-MSC-based therapies.
Bone marrow concentrate
Concentrated bone marrow aspirate was designed to 
increase the concentration of stem cells compared with 
naïve bone marrow aspirate and to avoid the lag time 
from diagnosis to treatment when culture-expanded 
BM-MSCs are used. In addition to the concentration of 
stem cells, the concentrations of platelets and therefore 
anabolic growth factors are increased [23]. When com-
bined with thrombin, the ﬁ  brinogen present in BMC is 
converted to ﬁ  brin and a solid scaﬀ  old forms to retain the 
cells and growth factors in a given location.
Tendonitis
No peer-reviewed preclinical or clinical reports on the 
use of BMC for tendonitis have been published. BMC is 
being applied clinically for ligament and tendon injuries 
in horses, but suﬃ   cient data are not currently available to 
assess its therapeutic potential.
Cartilage injury/osteoarthritis
In the equine model of acute cartilage injury discussed 
above (15-mm-diameter lesions), one limb was treated 
with BMC and microfracture and the other was treated 
with microfracture alone [23]. Re-check arthroscopy at 
3  months demonstrated signiﬁ   cantly improved repair 
tissue in BMC-grafted defects compared with micro-
fracture tissue with increased volume and greater inte-
gration of repair tissue with surrounding host cartilage. 
At 8 months, all macroscopic, histologic, and magnetic 
resonance imaging data indicated sustained improvement 
in BMC-grafted repair tissue in comparison with micro-
fracture. Like many other stem cell-based technologies, 
BMC is being applied in clinical veterinary and human 
patients, but no peer-reviewed results have been published.
Adipose-derived stromal vascular fraction cells
Th   e currently available technique uses a mixture of cells 
derived from adipose tissue surgically excised from 
horses or dogs. Th   e AD-SVF cells are simply isolated and 
injected into the patient without a cell culture step. 
Compared with cultured BM-MSCs, this technique has 
the advantage of supplying cells in a short time period 
(48 hours), and it should be remembered that although 
there are a large number of nucleated cells retrieved from 
the adipose digest, only a small percentage of nucleated 
cells are stem cells. In humans, 0.7% to 5% of nucleated 
cells in the stromal vascular fraction are stem cells [24].
Tendonitis
No references regarding the clinical application of AD-
SVF cells in equine tendonitis are currently available. 
Results of a pilot study demonstrated signiﬁ  cant  im-
prove  ment in histologic score in AD-SVF cell-treated 
tendons over phosphate buﬀ  ered saline-treated control 
tendons [25]. Although AD-SVF cells have been available 
for nearly 8 years and have been used to treat several 
thousand horses, no reports documenting their use in 
clinical cases of equine tendonitis have been published. 
AD-SVF cells are not approved by the US Food and Drug 
Administration for human application at this time.
Cartilage injury/osteoarthritis
As mentioned above, AD-SVF cell application in an 
equine model of early OA failed to result in any detec-
table improvement in articular health [19]. In fact, 
AD-SVF cells led to an increase in synovial ﬂ  uid concen-
tration of the proinﬂ  ammatory cytokine tumor necrosis 
factor-alpha. In dogs, two reports of improved clinical 
signs of OA after treatment have been published. In a 
double-blinded study assessing the use of AD-SVF cells 
in the hip joint of dogs, examining veterinarians (but not 
the dog owners) reported signs of clinical improvement 
[26]. In a second, uncontrolled study using AD-SVF cells 
for elbow OA, veterinarians and, to a lesser extent, 
owners both reported improvements in clinical signs 
[27]. Th  e disparity in the clinical beneﬁ  ts  noted  by 
owners in these studies investigating the use of AD-SVF 
cells in OA is unclear but perhaps suggests that any 
beneﬁ  t of AD-SVF cell application can be seen only in 
more advanced cases of OA or that changes in lameness 
associated with elbow OA in comparison with those of 
hip OA are more easily perceived by owners.
Debated hypothesis and the future of clinical stem 
cell therapy
Irrespective of the type of stem cell being investigated, 
the nature of the target tissue, or the species that is being 
treated, the fundamental questions underlying the 
clinical application of stem cells are the same and include 
the following: (a) What is the optimal tissue source of 
stem cells for each clinical application? In the current 
clinical applications of adult-derived stem cells, it is 
unlikely that a single stem cell source will be best for 
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onic germ layers (endoderm, mesoderm, and ectoderm). 
(b) How many stem cells are needed to eﬀ  ectuate 
regener  ation? Very few dose-response studies have been 
performed to date, and the available data suggest that 
‘more is not better’. (c) What is the best means to deliver 
the cells? Should they be administered locally to the site of 
damage or intravenously? Is a scaﬀ  old necessary, and if so, 
which scaﬀ  old is optimal for each tissue type? (d) Is there a 
requirement for co-delivery of growth factors to direct the 
function of the implanted cells? Many of these questions 
are intricately linked, and carefully designed research 
studies will be required to answer the debated theories.
Several avenues of stem cell therapy for tendon/
ligament pathologies are currently under investigation. 
Several types of stem cells not discussed herein, including 
ES cells, umbilical cord blood-derived stem cells, and iPS 
cells, show promise for regenerative applications. Finally, 
genetically modiﬁ  ed stem cells have been investigated in 
vitro and in vivo and show tremendous promise for 
enhancing organized repair of tendons and other 
musculoskeletal tissues.
Clinical uses of stem cells in reproductive medicine
Currently, there are no widespread uses of stem cell-
based therapies in reproductive medicine. However, the 
potential utility of such approaches makes them subjects 
of intensive research. Broadly speaking, two stem cell 
types are the primary topics of investigation: ES/iPS cells 
and spermatogonial stem cells (SSCs). Unfortunately, 
despite great eﬀ  ort, there are no completely characterized 
ES or iPS cells derived from species other than primates 
or mice [28]. For this reason, we focus here on SSCs, 
which are used in the techniques of testis xenografting 
and spermatogonial stem cell transplantation (SSCT).
Testis xenografting
Th  e primary clinical application for testis xenografting 
would be as a means to preserve the breeding potential of 
a genetically valuable pre-pubertal male animal [29]. For 
example, in the captive management of threatened or 
endangered species, speciﬁ  c individuals often have high 
genetic value. If adult males die before contributing their 
genes to the population, mature sperm can be collected 
and cryopreserved for future use in artiﬁ  cial insemination 
or a form of in vitro fertilization (IVF). If neonatal or 
juvenile males die, testis xenografting oﬀ  ers a means to 
develop sperm from their gonocytes or SSCs, which are 
present from parturition. In this procedure, small pieces 
(1 to 2 mm3) of donor testes are surgically grafted into 
immunodeﬁ  cient mice. In the absence of a functioning 
immune system, the recipient mice nurture the foreign 
testis tissue, which supports spermatogenesis [30]. By 
means of this approach, morphologically mature sperm 
have been produced in xenografts from a number of 
species, including rabbits [31], pigs and goats [30], ham-
sters [32], rhesus macaques [33], sheep [34], cats [35], 
and dogs [36]. However, the eﬃ   ciency of spermatogenesis 
in xenografts diﬀ  ers among species, with the bull [37-39], 
cats [35,40], and dogs [36] being less eﬃ   cient.  One 
common ﬁ  nding across species is that if the donor testis 
tissue has germ cells actively undergoing meiosis (as in 
puberty or adulthood), then the xenografts lose the 
ability to support spermatogenesis [40,41]. Th  e  fertilizing 
ability of graft-derived sperm has been veriﬁ  ed by the 
production of viable oﬀ  spring in allografted mouse [42] 
and xenografted rabbit [31] and pig [43]. Because there is 
no epididymis in this system, the functionally immature 
sperm can help generate oﬀ  spring only through intra-
cytoplasmic sperm injection (ICSI), a procedure in which 
sperm are injected directly into an oocyte. Th  us,  although 
banking of material from genetically valuable individuals 
of multiple species might begin now, the ultimate 
production of oﬀ   spring is restricted until ICSI is 
optimized for that species.
Spermatogonial stem cell transplantation
Th   e primary clinical uses of SSCT would be to preserve 
or manipulate the male germline or both [44]. Brieﬂ  y, the 
technique involves isolation of a mixed germ cell 
population from a donor testis (preferably enriched in 
SSC if markers are known for that species). Th  e  isolated 
cells are then injected in a retrograde fashion into the 
testes of a recipient animal. To increase the SSC niches 
that might be open for colonization, the recipients are 
often treated with focal testicular irradiation [45,46] or 
systemic busulfan [47,48] to reduce their endogenous 
SSC. After time is allowed for colonization, proliferation, 
and spermatogenesis, semen is collected and assessed for 
the relative percentage that is of donor origin. Although 
it has been performed successfully in several species, this 
technique has multiple steps that are technically 
challenging and time- and labor-intensive. Th   erefore, it is 
likely to be used in the future primarily as a clinical tool 
to develop transgenic biomedical research models or for 
the production of transgenic farm animals that produce 
tissues/organs genetically engineered to be compatible 
across species or to produce pharmaceutical proteins 
[49]. Xenogeneic transplantation has been attempted with 
various donor and recipient species. Unless the donor 
and recipient are closely taxonomically related (for exam-
ple, rat and mouse [50] as opposed to dog and mouse 
[51]), the recipient testes do not support spermatogenesis. 
Th   erefore, utilization for the conservation of threatened 
species would require not only the use of a suitable 
domestic animal recipient that would support spermato-
genesis of the donor but also some method of sorting the 
sperm of donor origin from that of recipient origin.
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technologies in clinical reproduction
Several questions need to be addressed in order to 
enhance the clinical utility of both testicular xenografting 
and SSCT approaches: Can markers that will label the 
SSC of various species be identiﬁ  ed?  Can  cryopreser-
vation methods for individualized SSC, pieces of testis 
tissue, and sperm be optimized? Can ‘downstream’ 
technologies such as classical IVF and ICSI be developed 
for diﬀ  erent species? Other questions are speciﬁ  c to one 
or the other technique: Why are there diﬀ  erences among 
species in the eﬃ   ciency of xenograft spermatogenesis? 
Why do xenografts from meiotic testes fail? Can we 
determine the critical parameters that deﬁ  ne  the 
taxonomic gulf between SSC donor species and the 
species that might be able to function as recipients?
Conclusions
Th  e clinical use of stem cells in veterinary medicine is 
clearly in its early stages. Applications for BM-MSC and 
AD-SVF cells in the treatment of musculoskeletal patho-
logies are currently in use in several species, although the 
diﬀ  erential eﬃ   cacies of various approaches are still being 
investigated. Optimization of these stem cell-based 
therapies will focus on cellular origin, isolation, enrich-
ment, and processing as well as on the timing, route of 
administration, formulation, and dosing of those thera  pies. 
Development of conﬁ  rmed ES or iPS cells in domestic 
species would greatly facilitate the development of a wider 
range of clinical applications. Use of stem cell-based 
approaches in attempts to preserve the germ plasm of 
threatened species could begin on an opportunistic basis 
in the form of xenografting of testis tissue obtained quickly 
after the death of pre-pubertal individuals. How  ever, this 
must still be considered a research endeavor given the 
largely unknown causes of species diﬀ   erences in the 
success of spermatogenesis as well as the need to perform 
subsequent techniques of assisted reproduction which 
have themselves not yet been determined for most species.
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